

# Author Index

## A

Abdelbaqi, M.Q., 177–200, 283  
Ahmed, S.A., 38  
Ali, M.M., 237  
Almhanna, K., 177–200  
Attard, G., 299, 301  
Azuma, K., 97

## B

Bach, V., 223  
Barghorn, A., 431  
Barwick, B.G., 297  
Becker, D., 512  
Bedoya, F., 155  
Beimfohr, C., 31  
Benlloch, S., 128  
Bepler, G., 101, 102  
Bezabeh, T., 156  
Bianco, R., 95  
Biasiotto, G., 226  
Blenkiron, C., 65, 66  
Bui, M.M., 397–413

## C

Calin, G.A., 64, 65  
Capuzzo, F., 89  
Carter, H.B., 288  
Ceppi, P., 97  
Charbonnier, F., 145, 146  
Chen, H.Y., 109  
Chen, Z.L., 189, 190  
Cheng, J.Q., 57–67, 259–275  
Chetty, R., 435  
Cheung, L., 36

Chou, T.H., 510  
Chuang, S.-T., 283–314  
Chuma, M., 216  
Clark, J., 297, 298  
Cohen, S., 80  
Cohen, Y., 27  
Concato, J., 306  
Conley, A., 397–413  
Coppola, D., 57–67, 119–157, 177–200,  
211–249, 259–275, 365–385,  
423–438  
Cukjati, M., 222  
Cuschieri, K., 370

## D

Diamond, M., 147  
Ducker, S., 75–109  
Dziadziuszko, R., 91

## E

Eberhard, D.A., 83  
Eisbrenner, K., 449–491  
Engelman, J.A., 94  
Esteller, M., 311  
Evans, D.G., 489  
Ezzat, S., 31

## F

Faber, A.C., 96  
Filipits, M., 108  
Fleming, W.H., 305  
Franklin, W.A., 127  
Fugazzola, L., 28

**G**

Gaudi, S., 497–512  
 Gauthier, M., 138  
 Ge, D., 245  
 Ghayouri, M., 365–385  
 Gilbert-Barness, E., 449–491  
 Gopalan, A., 300  
 Greenawalt, D.M., 185, 186  
 Greulich, H., 83, 95  
 Groskope, J., 292, 293  
 Gryfe, R., 137

**H**

Hakam, A., 119–157,  
 365–385  
 Halfon, P., 243  
 Han, S.W., 90, 92  
 Hanson, J.A., 358  
 Hatta, N., 508  
 Hawksworth, D., 305  
 Helm, J., 186  
 Henderson-Jackson, E.B.,  
 397–413  
 Hessels, D., 291  
 Hirish, S.M., 341–358  
 Hirsch, F.R., 80, 85, 87, 90  
 Hoshida, Y., 214, 236  
 Hotta, K., 86, 87  
 Howell, V.M., 43

**I**

Ichihara, S., 90  
 Ikeda, N., 97  
 Itoga, S., 191

**J**

Japa, S., 211–249  
 Järvinen, H.J., 145  
 Ji, H., 83  
 Johnson, S.M., 65  
 Jost, M., 293

**K**

Kalikaki, A., 85, 86, 92  
 Ke, H., 510  
 Khalil, F., 75–109  
 Khan, M., 434  
 King, J.C., 298  
 King, M.C., 378  
 Kleiber, J., 242

Kobayashi, S., 94  
 Kong, W., 57–67,  
 259–275  
 Kosaka, T., 87, 109  
 Kresak, J., 1–13  
 Kvols, L.K., 423–438

**L**

Ladanyi, M., 345  
 Laken, S.J., 135  
 Lamarcq, L., 371  
 Laxman, B., 313  
 Lee, H.W., 97  
 Lee, J.M., 236  
 Lee, W.H., 224  
 Lee, Y.J., 84  
 Lewis, S.J., 191  
 Lewis, X., 335  
 Li, J., 108  
 Lindh, M., 236  
 Liu, W.C., 235  
 Llovet, J.M., 246  
 Lynch, T.J., 85

**M**

Ma, X.J., 63  
 Magi-Galluzzi, C., 297  
 Malafa, M., 211–249,  
 259–275  
 Marchetti, A., 105  
 Margraf, R.L., 39  
 Marino, M.E., 329–337  
 Marks, J.L., 87  
 Mathieu, A., 92  
 Mayhall, G., 211–249  
 McCardle, T.W., 497–512  
 McCarthy, J.J., 245  
 McNab, P.M., 497–512  
 McRonald, F.E., 194  
 Meredith, K., 177–200  
 Messina, J.L., 497–512  
 Metzler, M., 65  
 Michael, M.Z., 65  
 Miller, V.A., 105  
 Miller-Mosin, K., 509  
 Millonig, G., 180  
 Mitsudomi, T., 83–85  
 Moldawer, M.P., 426  
 Montosi, G., 227  
 Moore, P.S., 432  
 Muhammad, J., 423–438  
 Murff, H.J., 155

**N**

Nasir, A., 119–157, 211–249, 423–438  
 Nasir, N.A., 423–438  
 Niell, B.L., 137  
 Nikiforova, N.M., 35

**O**

Okamoto, H., 234

**P**

Paez, J.G., 85  
 Pao, W., 85, 94, 105  
 Park, I.H., 84, 105  
 Park, K., 301  
 Parr, R.L., 303  
 Parra, H.S., 92  
 Peker, D., 521–545  
 Pelengaris, S., 434  
 Peukert, S., 509  
 Piccioli, P., 138  
 Politi, K., 83  
 Pott, P., 345  
 Potti, A., 109  
 Powell, S.M., 133

**Q**

Qin, D., 329–337  
 Quigley, B., 75–109

**R**

Regales, L., 96  
 Rho, J.K., 95  
 Richards, E.J., 259–275  
 Richards, T., 57–67  
 Riely, G.J., 104  
 Roetto, A., 225  
 Rosell, R., 101, 108  
 Rowe, L.R., 28  
 Ruiz-Aragón, J., 295

**S**

Sadow, P.M., 33  
 Sánchez, M., 222  
 Santos, P.C., 218, 227  
 Sapio, M.R., 26  
 Sato, H., 305  
 Savell, J., 19–45  
 Scholl, U.I., 88  
 Selaru, F.M., 185

Sempere, L.F., 66  
 Sexton, W.J., 283–314  
 Shackelford, R.E., 19–45, 119–157, 177–200,  
 211–249, 283–314, 341–358, 365–385  
 Shan, Y., 1–13  
 Sharon, M., 341–358  
 Sheu, S.Y., 42  
 Shibata, D., 119–157  
 Shigematsu, H., 87  
 Sholl, L.M., 90  
 Sihto, H., 511  
 Silber, J., 10  
 Soh, J., 104  
 Souglakos, J., 101  
 Spiess, P.E., 283–314  
 Stemper, T.J., 147  
 Stott, M.K., 220, 222  
 Strosberg J. R., 423–438  
 Suriano, G., 198

**T**

Tadokoro, K., 239  
 Takahashi, S., 187, 188  
 Takamizawa, J., 65  
 Takane, H., 153  
 Takano, E.A., 379  
 Takano, T., 39, 40, 87, 90  
 Tao, J., 521–545  
 Tibaldi, C., 98  
 Tol, J., 129  
 Tomlins, S.A., 295, 297, 302, 303  
 Trimaldi, J., 283–314  
 Tsao, M.S., 91  
 Tsiatis, A.C., 127

**V**

van't Veer, L.J., 62  
 Varella-Garcia, M., 89  
 Vasen, H.F.A., 145  
 Vasko, W., 31  
 Vener, T., 313  
 Verbeek, J., 243  
 Vijver, M.J., 62  
 Volikos, E., 151

**W**

Wang, J., 300  
 Wang, Q., 232, 233  
 Wang, W., 101  
 Wang, X., 97  
 Wang, Y., 63

Whitaker, H.C., 290  
Whitling, N.A., 341-358  
Whitman, E.J., 294  
Wu, Y., 141

**X**

Xu, X., 100

**Y**

Yang, J., 247  
Yang, Y.J., 249  
Yeatman, T., 119-157  
Yin, Z., 98

Yoshida, K., 86  
Yoshimoto, M., 299  
Yoshioka, H., 85

**Z**

Zhang, L., 521-545, 557-579  
Zhang, X., 557-579  
Zheng, Z., 102  
Zhou, W., 98  
Zhu, C.Q., 90  
Zhu, Z., 30  
Zhuang, H.Q., 95  
Zikusoka, M.N., 430  
Zynger, D.L., 329-337

# Subject Index

## A

AAMs. *See* Aggressive angiomyxomas (AAMs)  
Acetaldehyde dehydrogenase (ALDH2), 190–193  
Acute lymphoblastic leukemia (ALL), 564, 574  
Acute myeloid leukemia (AML), 559–561, 573, 576  
Acute promyelocytic leukemia (APL), 560, 574, 577, 661  
Adenocarcinoma, 78–84, 88, 91, 92, 95, 96, 98, 101, 104, 106, 107, 109  
Adrenal cortical carcinoma, 472  
Adrenocortical tumors, 455  
African American men, 286, 287, 290, 297  
Aggressive angiomyxomas (AAMs), 346  
AKT, 11  
Alcohol abuse, 180, 181  
Alcohol flushing, 191  
ALDH2. *See* Acetaldehyde dehydrogenase (ALDH2)  
ALK rearrangements, 107–108  
ALL. *See* Acute lymphoblastic leukemia (ALL)  
Allele-specific PCR (ARMS), 222  
Alpha ( $\alpha$ )-fetoprotein (AFP), 217  
Alpha-methylacyl-CoA racemase (AMACR), 289, 311  
AML. *See* Acute myeloid leukemia (AML)  
Amplicon, 185, 192, 199  
Amplification refractory mutation system, 87  
Anaplasia, 459–460  
Angiogenesis, 4, 8–10  
APC, 130–139

APL. *See* Acute promyelocytic leukemia (APL)  
ARMS PCR, 126  
Artificial intelligence classification algorithm, 274  
Ashkenazi, 377–379  
ASPL-TFE3 fusion, 336  
Astrocytomas, 2  
Attenuated FAP, 136  
Autosomal dominant transmission, 458

## B

B-ALL. *See* B-lymphoblastic leukemia/lymphoma (B-ALL)  
Basal cell carcinoma (BCC), 475, 507–510  
B-cell lymphoma 2 (Bcl-2), 287, 289, 305, 306  
B cell prolymphocytic leukemia (B-PLL), 536  
Bcl-2. *See* B-cell lymphoma 2 (Bcl-2)  
Beckwith-Wiedemann syndrome (BWS), 455  
Biomarker, 289, 298, 313  
Biopsy, needle core, 459  
Birt-Hogg-Dubé syndrome, 462  
BL. *See* Burkitt lymphoma (BL)  
B-lymphoblastic leukemia/lymphoma (B-ALL), 524, 528, 532  
Bmi-1, 216  
*BMPRIA*, 148, 149  
Bone tumor, 404, 405  
BPSA. *See* Prostate-specific antigen, benign  
BRAF, 7, 128, 373–374, 376, 502–504, 512  
*BRAF2*, 29  
BRAF V600E, 24–28, 33, 42  
*BRAF V600E* mutation, 144

- Brain tumors, 480–481  
 astrocytoma, 480  
 atypical neurocytoma, 481  
 central neurocytoma, 481  
 desmoplastic infantile astrocytoma, 480–481  
 dysembryoplastic neuroepithelial tumor, 481  
 gangliocytomas, 480  
 ganglioglioma, 480–481  
 Peutz-Jeghers syndrome, 480
- Branched chain DNA (bdNA), 231–233
- BRCA1. *See* Breast cancer 1 (BRCA1)
- BRCA2. *See* Breast cancer 2 (BRCA2)
- Breast cancer, 58
- Breast cancer 1 (BRCA1), 60–61, 66, 108, 376–378, 380, 385  
 management of patients, 380
- Breast cancer 2 (BRCA2), 376–378, 380  
 management of patients, 380–381
- Breast carcinoma, 473
- Burkitt lymphoma (BL), 479, 524, 525, 535, 541–543
- C**
- CAM17.1 antibody, 265
- CA-242 marker, 265
- Camellia sinensis*, 196
- Cancer linkage, 198
- Cancer outlier profile analysis (COPA), 295, 302
- Carbohydrate antigen 19–9, 264–265
- Carcinoembryonic antigen (CEA), 38–40, 265, 266, 268
- Carcinogenesis, mechanisms in, 452
- Carcinosarcoma, 383
- Carney complex, 356, 357
- Cartilagenous tumors, 404
- $\beta$ -Catenin, 373, 374, 382
- CD117, 351
- Cdx2, 193
- CEA. *See* Carcinoembryonic antigen (CEA)
- Cell(s), nephrogenic blastemal, 457
- Cell cycle, 433–436, 438
- Central nervous system (CNS), 489–491
- Cervical cancer, 367
- Cetuximab, 125
- CGH. *See* Comparative genomic hybridization (CGH)
- Chemotherapy, 78–80, 86–88, 90, 92, 93, 97–99, 102, 105–107, 109
- Choriocarcinoma, 353, 469
- Chromaffin cells, 472
- Chromosomal translocation, 289, 303, 347
- Chromosome 22, 461
- Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 534
- Circulating tumor cells (CTCs), 274
- Cisplatin, 79, 86, 97, 98, 101, 103, 108
- c-KIT, 199, 200, 503
- Clear cell carcinoma of the kidney, 461
- c-MET, 32–33, 44
- C-MYC, 289, 304, 305
- Colorectal carcinoma, 122
- Comparative genomic hybridization (CGH), 351, 352, 430–432, 437, 504, 505
- Comprising chronic myelomonocytic leukemia (CMML), 570
- Conformational polymorphism, 429
- Conformation strand gel electrophoresis (CSGE), 134
- Congenital mesoblastic nephroma, 462
- COPA. *See* Cancer outlier profile analysis (COPA)
- Core binding factor (CBF), 569
- Cowden syndrome, 491
- CpG island methylation, 435
- Cryptorchidism, 349
- Cyclase-associated protein 2 (CAP2), 217
- Cyclin-dependent kinase inhibitors, 506, 507
- CYGB* gene, 194, 195
- Cystic nephroma (CN), 460–461
- Cystic partially differentiated nephroblastoma, 460–461
- Cytokeratins, 267–268
- D**
- Denys-Drash syndrome, 458
- Dermatofibrosarcoma protuberans, 476
- Desmoplastic small round cell tumors (DSRCTs), 347, 467
- Developmental anomalies, 453
- Diagnostic algorithms, 523–527, 561–563
- Differentiation  
 epithelial structures, 459  
 stromal, 459
- Diffuse large B cell lymphoma, 525, 534, 540–541
- 2-Dimension gel electrophoresis, 8
- DNA, 452  
 methylation, 454  
 heteroduplexes, 379  
 ploidy, 335  
 sequencing, 26–31, 35, 38, 222–223

- DPC4/Smad4* gene, 432  
 DSRCTs. *See* Desmoplastic small round cell tumors (DSRCTs)
- E**  
 E-cadherin, 190, 197, 198, 435, 438  
 EGFR. *See* Epidermal growth factor receptor (EGFR)  
 ELM4-ALK, 106, 107  
 Embryonal carcinoma, 353, 469  
 Embryonal tumors, 482–483  
   medulloblastoma, 482–483  
   melanotic medulloblastoma, 482  
 EMT. *See* Epithelial to mesenchymal transition (EMT)  
 Endometrial carcinomas, 381–383  
 Ependymoblastoma, 484  
 Ependymomas, 2  
 Epidermal growth factor receptor (EGFR), 8–10, 80–96, 103–107, 123–125, 127, 129  
   EGFRvIII (delta EGFR), 8  
 Epigenesis, 453  
 Epigenetic alterations, 274  
 Epithelial to mesenchymal transition (EMT), 274  
 ERCC1. *See* Excision-repair cross complementing-1 protein (ERCC1)  
*ERG* expression, 295, 296, 299, 300, 302, 313  
 Erythroblast transformation-specific transcription factor family, 297  
 Esophageal adenocarcinomas, 179  
*ETV1* expression, 295, 296, 302  
*ETV6-NTRK3* gene, 473  
 Ewing sarcoma (EWS), 399, 406, 407, 410, 411, 455, 468–469  
 Excision-repair cross complementing-1 protein (ERCC1), 80, 96–103, 108  
 Exon 20, 83, 85, 95  
 Expression profile, 61  
 Extrarenal malignant rhabdoid tumor, 468
- F**  
 Familial adenomatous polyposis (FAP), 130–133, 135–139, 147, 478  
 Familial medullary thyroid cancer (FMTC), 38, 41, 42  
 Familial melanoma, 499  
 FAP. *See* Familial adenomatous polyposis (FAP)  
 Fibroblast Growth Factor receptor 3 gene (FGFR3), 331
- Fibronectin, 436, 437  
 Fine needle aspirate (FNA), 523  
 Fluorescence in-situ hybridization (FISH), 6, 88–92, 106, 332–337, 504–506  
 FMTC. *See* Familial medullary thyroid cancer (FMTC)  
 Follicular carcinoma, 34–37  
 Follicular lymphoma, 525, 534, 535, 539–540  
 Fumonisin, 181
- G**  
 Gametogenesis, 455  
 Gastric cancer, 195, 196, 198, 199  
 Gastrinomas, 427, 428, 431–435  
 Gastro-esophageal malignancies, 200  
 Gastro-esophageal reflux, 184, 194  
 Gastrointestinal stromal tumor (GIST), 199, 200, 399, 400, 402, 408  
 Gastrointestinal tumors, 479  
   mesenchymal, 479  
   stromal tumors, 479  
 Gene cluster, 185  
 Gene expression, 456  
   controlling, 453–454  
   profiling, 435–437, 578, 579  
   sequential, 456  
 Gene regulation, monoallelic, 455  
 Genetic alterations, 79–80  
 Genome-wide association study (GWAS), 272, 500, 501  
 Genomic imprinting, 489  
 Germ cell tumors, 348–354, 358  
 Germline, 427, 429  
 GIST. *See* Gastrointestinal stromal tumor (GIST)  
 Glioblastoma, 3–6, 8, 10, 12  
   primary glioblastomas, 3  
   secondary glioblastomas, 3–6, 8–10  
 Gliogenesis, 3  
 Gliomas, 3–13  
 Glutamine synthetase (GS), 216  
 Glutathione-S-transferase (GSTs), 310  
 Glycosylated proteins, 268  
 Glypican-3 (GPC3), 217  
 Golgi phosphoprotein 2 (GOLPH2), 313  
 Gonadoblastoma, 350, 470–471  
 Gorlin syndrome, 490  
 Granulosa cell tumors, 358  
 Growth differentiation factor, 267  
 GWAS. *See* Genome-wide association study (GWAS)  
 Gynecologic malignancies, 366, 385

**H**

Hamartomatous polyposis, 147–152  
 Hashimoto's thyroiditis (HT), 33  
 Heat shock protein 70 (HSP70), 215–216  
 Hedgehog signaling pathway (Hh signaling pathway), 508, 512  
*Helicobacter pylori*, 182, 195–196  
 Hemochromatosis, 225–227  
 Hepatitis B virus (HBV), 228–241  
 Hepatitis C virus (HCV), 228, 241–245  
 Hepatoblastoma, 455, 466–467  
 Hepatocarcinogenesis, 214–215  
 Hepatocellular carcinoma (HCC), 212  
   dysregulated/mutated, 248–249  
   gene expression proflin, 246–247  
   immunostain combinations, 217–218  
   microRNA, 247  
   molecular-genetic testing, 218  
   promoter methylation, 247–248  
 Hereditary diffuse gastric carcinoma, 196–198, 200  
 Hereditary hemochromatosis  
   genetic testing, 227–228  
   HFE testing, 218–219  
   indications, 218–219  
   juvenile hemochromatosis, 224–225  
   SLC40A1 gene mutation, 227  
   transferrin 2 gene mutation, 225–227  
 HER-2/neu, 436  
 Heteroduplex DNA, 192  
 Hh signaling pathway. *See* Hedgehog signaling pathway (Hh signaling pathway)  
 High-grade urothelial carcinoma, 331  
 High-resolution melting analysis (HRM), 126, 378  
 Histopathologically, 44  
 HJV gene analysis, 224–225  
 Hormonal factors, 23  
 HPV. *See* Human papilloma virus (HPV)  
*H. pylori*. *See* *Helicobacter pylori*  
 HRM. *See* High-resolution melting analysis (HRM)  
 Human glandular kallikrein (hK2), 306  
 Human mitochondrial genome, 272  
 Human papilloma virus (HPV), 343–346, 367–372, 384, 471, 510  
   DNA-based HPV testing, 371  
   DNA testing by hybrid capture, 372  
   E6 gene product, 343  
   E7 gene product, 343  
   type 11, 471  
   type 16, 471  
 Hürthle cell, 32, 35, 37

Hybridization, 344, 345, 351–353  
 Hydatidiform mole, 385  
 Hypermethylation, 263, 275  
 Hypermethylation of CpG islands, 269

**I**

*I1307K* mutation testing, 137  
 Immunohistochemical staining, 4, 5  
 Incidence, 452  
 INNO-LiPA HBV assay, 237–238  
 Insulin-like growth factor (IGF2), 434–436, 458  
 Intercellular signaling, sonic hedgehog, 456  
 Intestinal metaplasia, 195  
 Intraductal papillary mucinous neoplasms (IPMNs), 262, 264, 267  
 Intratubular germ cell neoplasia, unclassified (ITGCNU), 349–352  
 Intratumoral clonal expansion, 273  
 IPMNs. *See* Intraductal papillary mucinous neoplasms (IPMNs)  
 Islets of Langerhans, 425  
 Isocitrate dehydrogenase, 3  
   IDH1, 3–4, 10  
   IDH2, 3–4  
 ITGCNU. *See* Intratubular germ cell neoplasia, unclassified (ITGCNU)

**J**

JPS. *See* Juvenile polyposis syndrome (JPS)  
 Juvenile granulosa cell tumor, 470  
 Juvenile hemochromatosis (JH), 224–225  
 Juvenile laryngeal papillomatosis, 471  
 Juvenile papillomatosis, 474  
 Juvenile polyposis syndrome (JPS), 147–149

**K**

Kallikrein, 306  
   human kallikrein 2, 306–308  
 Ki-67, 506  
 Kidney tumors, 336–337  
 Koilocytotic atypia, 344  
 KRAS, 25, 29, 31, 33, 35, 38, 44, 79, 80, 87, 90, 100, 103–107, 124  
 KRAS2, 263, 270  
 KRAS point mutations, 270, 273

**L**

Large cell calcifying sertoli cell tumor, 470  
 LCCSCTs. *See* Sertoli cell tumors, large cell calcifying



- LCTs. *See* Leydig cell tumors (LCTs)
- Leiomyomatosis, 462
- Leiomyosarcomas, 348
- Lewis-a secretor status, 265
- Leydig cell tumors (LCTs), 355, 357, 470
- Li-Fraumeni syndrome. *See* Tumor syndromes
- Liposarcomas, 347
- LKB1/STK11*, 150
- Loss of heterozygosity (LOH), 7, 9, 273, 427, 431–433
- 10q LOH, 9
- Loss of imprinting, cancer, 455
- Low-grade urothelial carcinoma, 330, 331
- Lymphoid neoplasms, 523–525, 534, 559, 560, 569
- Lymphoplasmacytic lymphoma, 535, 537
- Lynch syndrome, 130, 140, 384
- M**
- Malformation syndromes, 457
- Mammalian target of rapamycin (mTOR), 429, 430, 438
- MammaPrint®, 58, 62–63
- Mammary development, 59
- Mantle cell lymphoma, 525, 527, 534–536, 540
- MAP. *See* MYH-associated polyposis (MAP)
- MAPK. *See* Mitogen-activated protein kinase (MAPK)
- Mass spectroscopy (MS), 8
- Mastocytosis, 560, 563, 568, 569, 578
- Maté, 182
- Mature B cell neoplasms, 523, 534
- MCNs. *See* Mucinous cystic neoplasms (MCNs)
- McPyV. *See* Merkel cell polyomavirus (McPyV)
- MDM2 antagonists, 401, 403, 404, 406, 410, 411
- MDS. *See* Myelodysplastic syndrome (MDS)
- Medullary thyroid cancer (MTC), 29, 37–42
- Medulloepithelioma, 483–484
- Melanocortin, 500
- Melting curve analysis, 191–193
- MEN. *See* Multiple endocrine neoplasia (MEN)
- MEN2A. *See* Multiple endocrine neoplasia types 2A (MEN2A)
- MEN2B. *See* Multiple endocrine neoplasia types 2A (MEN2B)
- Meningioma, 485–486
- Mental retardation. *See* WAGR syndrome
- Merkel cell carcinoma, 511
- Merkel cell polyomavirus (McPyV), 511, 512
- Mesangial sclerosis. *See* Denys-Drash syndrome
- Mesenchymal neoplasms, 398, 399
- Mesothelioma, 343, 345
- malignant mesothelioma, 348
- Metabolomics, 156
- Metastatic liver disease, 249
- Methylation-specific PCR (MSP), 311
- Methylation-specific pyrosequencing, 5
- Micoarray(s), 10, 155
- Microarray analysis, 184–187, 189, 191
- Microdeminoprotein-β (MSMB), 289–291
- MicroRNA-155, 65, 66
- MicroRNAs (miRNAs), 188–190, 247, 270–271, 312
- miR-21, 10, 12
- miR-128, 10, 13
- miR-181, 13
- miR-221/222, 12
- Microsatellite, 124, 143
- Minimal residual disease (MRD), 524, 527, 532, 565, 575, 579
- miR-155. *See* MicroRNA-155
- miRNA profiles, 65, 66
- miRNAs. *See* MicroRNAs
- miRNome, 271
- Mismatch repair gene, 7
- Missense mutations, 6
- Mitochondrial mutations, 303, 304
- Mitogen-activated protein kinase (MAPK), 501, 503
- MAPK pathway, 501, 504
- Mixed Germ Cell Tumor, 469
- Mixed lineage leukemia (MLL), 529, 533
- Mixed oligodendrogliomas, 2
- Molecular diagnostics, 259–275
- Molecular studies
- FISH, 465
- FKHR, 466
- Moles
- complete, 455
- partial, 455
- MRD. *See* Minimal residual disease (MRD)
- mRNA, 91, 96–98, 100, 102
- MSH2* and *MLH1* mutations, 141
- MSH6* mutation, 7
- MSMB. *See* Microdeminoprotein-β (MSMB)
- MSP. *See* Methylation-specific PCR (MSP)
- MTC. *See* Medullary thyroid cancer (MTC)
- mTOR. *See* Mammalian target of rapamycin (mTOR)
- MUC1, 187
- Mucinous cystic neoplasms (MCNs), 262

- Multiple endocrine neoplasia (MEN),  
426–427, 472, 473
- Multiple endocrine neoplasia types 2A  
(MEN2A), 29, 41–43
- Multiple endocrine neoplasia types 2B  
(MEN2B), 38, 39, 41
- Multiplex PCR, 235–236
- Mutation, 79–81, 83–96, 99, 100, 103–109
- MUTYH* mutations, 131, 138–140
- Myelodysplastic syndrome (MDS), 559, 560,  
562–564, 571, 573, 576
- Myeloid neoplasm, 559–561, 563, 573,  
576, 579
- Myeloproliferative neoplasm, 559, 560,  
562–570, 573
- MYH-associated polyposis (MAP), 129, 130,  
138, 139
- N**
- NAMPT. *See* Nicotinamide  
phosphoribosyltransferase (NAMPT)
- Natural killer, 523
- Nephroblastoma. *See* Wilms' tumor
- Nephroblastomatosis, 460
- Nephrogenic rests, 460
- Neuroblastoma, 463–465  
differentiating, 463  
intermixed, 463  
nodular, 463  
poorly differentiated, 463  
undifferentiated, 463
- Nicotinamide phosphoribosyltransferase  
(NAMPT), 187, 376
- N*-nitroso compounds, 196
- Nodular (desmoplastic) medulloblastoma, 482
- Non-small cell lung cancer (NSCLC), 78, 82
- Non-steroidal anti-inflammatory drugs  
(NSAIDs), 183
- Northern blots, 10
- NRAS*, 31, 33, 35, 129
- N-RAS*, 504
- NSAIDs. *See* Non-steroidal anti-inflammatory  
drugs (NSAIDs)
- NSCLC. *See* Non-small cell lung cancer  
(NSCLC)
- Nucleic acid hybridization assays, 230–231
- O**
- Oligodendrogliomas, 2
- Oligonucleotide microchip arrays, 236–237
- O*<sub>6</sub>-methylguanine-DNA methyltransferase, 5
- Oncogenes, 10, 38, 44
- Oncogenic mutation, 403
- Oncotype DX®, 59, 62, 64
- Opium, 182
- Osteopontin (OPN), 266–267
- Osteosarcoma, 399, 404–406, 474–475
- Ovarian cancer, 373  
granulosa cell tumors, 375
- Oxidative stress, 272
- P**
- 11p13, 458
- p16, 369
- p53, 5, 6, 10, 12, 368, 370, 382–384, 460, 500,  
509–511
- Pancreatic cancer, 259–275
- Pancreatic intraepithelial neoplasias (PanINs),  
262, 268
- Pancreatoblastoma, 479–480
- PanINs. *See* Pancreatic intraepithelial  
neoplasias (PanINs)
- Panitumumab, 125
- Papillary thyroid carcinoma, 24–33
- Parafibromin, 43
- Paratesticular tumors, 469–470
- Parathyroid, 21, 22, 43–45
- Parathyroid adenoma (PA), 426
- Parathyroid cancer (PC), 22, 43, 44
- Parathyroid tumor, 43
- Pax-2*, 458
- PAX8-PPAR-gamma*, 35, 36, 42
- PC. *See* Parathyroid cancer (PC)
- PCa. *See* Prostate cancer (PCa)
- PCA3. *See* Prostate cancer gene 3 (PCA3)
- PCR. *See* Polymerase chain reaction (PCR)
- Penile cancer, 342
- Periapillary adenocarcinomas, 267
- Peutz-Jeghers syndrome, 199
- Pheochromocytoma, 455, 472–473
- Phyllodes tumor, 474
- Pigmented villonodular synovitis (PVNS),  
401, 409
- PIK3CA, 129
- Pilocytic astrocytomas, 3, 7
- Pineoblastoma, 484–485
- Pineocytoma, 484
- P16INK4/p14ARF, 433
- Placental-like alkaline phosphatase, 350
- Plasma cell myeloma, 535, 537–538
- Plasminogen activator, 186
- PMF. *See* Primary myelofibrosis (PMF)
- PNET. *See* Primitive neuroectodermal  
tumors (PNET)
- Point mutation, 263, 270, 273

- Polycistron, 189  
 Polycyclic aromatic hydrocarbons, 181, 182  
 Polyembryoma, 349, 355  
 Polymerase chain reaction (PCR), 4, 6–8, 10  
   invader assay, 238–240  
   methylation-specific, 5  
 Polymorphism(s), 98, 99, 102, 103  
 Polymorphism testing, 27–28  
 12p Overexpression, 352  
 1p/19q co-deletion, 6  
 Precursor lymphoid neoplasms, 527  
 Predictive value, 79, 82, 89–92, 96–98,  
   100–101, 104–108  
 Primary myelofibrosis (PMF), 559, 560,  
   563, 568  
 Primitive neuroectodermal tumor (PNET),  
   399, 400, 404, 411, 413, 468–469  
 Prohibitin, 9  
 Promoter hypermethylation, 5  
 Prostate cancer (PCa), 285–300, 302–314  
 Prostate cancer gene 3 (PCA3), 289,  
   291–295, 313  
 Prostate-specific antigen (PSA), 285–295, 299,  
   306, 307  
   benign, 288  
   test, 287, 289  
   velocity, 288  
 Proteomics, 7, 9, 156  
 PSA. *See* Prostate-specific antigen (PSA)  
 PTCH1 gene, 508  
 PTEN, 8, 9, 12, 24, 34–36, 373, 375, 382, 383,  
   430, 432  
*PTEN* loss, 298, 299, 313  
 Pulmonary disease, 471  
 Pulmonary tumors, 476–478  
   Askin tumor/small round cell tumor, 478  
   bronchogenic carcinoma, 478  
   inflammatory myofibroblastic tumor, 476  
   mucoepidermoid tumor, 477  
   pleuropulmonary blastoma, 476–477  
   primary pulmonary carcinoid, 477  
   pulmonary metastatic disease, 478  
 PVNS. *See* Pigmented villonodular synovitis  
   (PVNS)  
 Pyrosequencing, 345
- Q**
- 13q14 locus, 487
- R**
- Radiotherapy, 469  
 RAS, 501, 503, 510  
 Recurrent translocation, 399, 401, 411  
 Renal cell carcinoma, 336, 462–463  
   CD10, 462  
   cytokeratin, 462  
   vimentin, 462  
 Renal rhabdoid tumor, 461–462  
 Restriction length polymorphism, 270  
 Retinoblastoma, 486–487  
   hereditary, 487  
   trilateral retinoblastoma, 487  
 RET mutations, 29, 32, 38, 39, 41, 42  
*Ret proto-oncogene*, 29  
 Reverse transcriptase PCR (RT-PCR), 242  
 Rhabdoid tumor, 483  
 Rhabdomyosarcoma (RMS), 347, 348, 455,  
   465–466  
   alveolar, 466  
   embryonal, 465–466  
 Ribonucleotide reductase, 80, 99–103  
 Ribonucleotide reductase subunit 1 (RRM1),  
   80, 97, 99–103, 108  
 Risks factors, 22–23  
 RMS. *See* Rhabdomyosarcoma (RMS)  
 RNA, 184–186, 188, 190, 194  
 RNA induced silencing complex (RISC), 271  
 Rosettes, 487  
   Homer-Wright, 487  
   pseudorosettes, 487  
 RRM1. *See* Ribonucleotide reductase subunit  
   1 (RRM1)  
 RUNX1T, 437
- S**
- SAGE. *See* Serial analysis of gene expression  
   (SAGE)  
 Sanger sequencing, 345  
 Sarcoma  
   adjuvant therapy, 408  
   clinical trials, 407, 409  
   radiation, 407  
 SCC. *See* Squamous cell carcinoma (SCC)  
 Schwannian stroma, 465  
 SDHD. *See* Succinate dehydrogenase subunit  
   D (SDHD)  
 SELDI ProteinChip Arrays, 273  
 Seminomas, 351, 469  
 Serial analysis of gene expression  
   (SAGE), 269  
 Serine peptidase inhibitor, Kazal type 1  
   (SPINK1), 289, 302, 303, 313  
 Sertoli cell tumors, 355, 356, 470  
   large cell calcifying, 355, 356  
   sclerosing, 355, 356

- Sertoli-Leydeg cell tumor, 357  
 Serum RNA, 187  
 Shifted termination assay technology (STAT), 25–28  
 Single nucleotide polymorphisms (SNPs), 286, 312, 527, 532  
 Skin tumors, 475–476  
 SMAD4, 148, 149, 264  
 Smokers, 78, 80–84, 88, 104, 107  
 SNPs. *See* Single nucleotide polymorphisms (SNPs)  
 Spermatocytic seminoma, 349, 354  
 SPINK1. *See* Serine peptidase inhibitor, Kazal type 1 (SPINK1)  
 Splenic marginal zone lymphoma, 535–537  
 Squamous cell carcinoma (SCC), 78–80, 84, 91, 108, 475–476, 508–511  
 Squamous intraepithelial lesions, 369  
 Staining  
   *bcl2*, 461  
   CD10, 462  
   CD56, 460  
   CD99, 461  
   CEA, 462  
   chromogranin, 473  
   cytokeratin, 459, 461, 462  
   EMA, 462, 473  
   low-grade central, 475  
   NB84, 465  
   osteopontin/osteonectin, 474  
   parosteal, 475  
   S100 positive, 465  
   telangiectatic, 475  
   vimentin, 461, 462, 469  
   WT1, 461  
 STAT. *See* Shifted termination assay technology (STAT)  
 Succinate dehydrogenase subunit D (SDHD), 432  
 Supratentorial PNET/CNS-PNET, 482–483  
 Symptoms  
   anemia, 468  
   elevated sedimentation rate, 468  
   elevated serum AFP, 469  
   fever, 468  
   leukocytosis, 468  
   soft tissue mass, 468  
 Synovial sarcoma, 401, 407, 409, 410
- T**  
 T-ALL. *See* T-lymphoblastic leukemia/lymphoma (T-ALL)  
 Telomerase, 370  
 Temozolamide, 5  
 Teratoma, 469, 477  
   cardiac, 477  
 Testicular sex-cord stromal tumors, 470–471  
 Testicular tumors, 469–470  
 TFE3 protein, 336  
 Theros®, 59, 63–64  
 Thrombomodulin, 435, 438  
 Thyroid, 21–23, 25, 27–29, 32–40, 42, 44  
 Thyroid carcinoma, 471–472  
   C-cell hyperplasia, 472  
   follicular, 471–472  
   medullary, 472  
   papillary, 471  
 Tissue Inhibitor of Matrix Metalloproteinase 1 (TIMP-1), 266  
 Tissue polypeptide specific antigen (TPS), 266  
 TKI. *See* Tyrosine kinase inhibitors (TKI)  
 T-lymphoblastic leukemia/lymphoma (T-ALL), 524, 528  
*TMPRSS2*  
   *ERG* fusion, 296–302, 305, 313  
   *ERG* gene fusion, 294  
   *ETS* expression, 298, 299  
   *ETS* fusion, 298, 300, 301  
 T/Natural killer (NK) cell lymphomas, 543  
 TNM classification, 60  
 Tobacco, 179, 181, 182  
 TP53 gene, 331  
 TPS. *See* Tissue polypeptide specific antigen (TPS)  
 Transcriptome, 184, 193  
 Transferrin 2 gene mutation (TFR2), 225–227  
 Translocation, 468  
   t(7;22)(p22;q12), 468  
   t(11;22)(q24;q12), 468  
   t(21;22)(q22;q12), 468  
 Trisomy 12, 536, 540  
 Tuberosus sclerosis, 462  
 Tumor-specific marker, 4  
 Tumor suppression, hsNF5/INI1, 461  
 Tumor suppressor, 5, 9, 10, 12  
 Tumor syndromes  
   Cowden syndrome, 491  
   Gorlin syndrome, 490  
   Li-Fraumeni syndrome, 491  
   neurofibromatosis type 1, 489  
   neurofibromatosis type 2, 489

tuberous sclerosis, 489–490  
von Hippel-Lindau disease, 490  
Turcot syndrome. *See* Tumor syndromes  
Tylosis, 184, 194–195  
Tyrosine kinase inhibitor (TKI), 80, 81, 83–96,  
105–107, 529

**U**

Ubiquitin, 428  
UGT1A1, 152–155  
UGT1A1\*1, 152–154  
UGT1A1\*28, 152–154  
Urinary cytology, 331  
Urine cytology, 331, 332, 335  
Urokinase plasminogen activator  
uPA, 308, 309  
uPAR, 308–310  
Urothelial carcinoma, 330–336  
UroVysion™, 332–336  
Uterine serous carcinoma (USC), 382

**V**

Veridex®, 63  
VHL gene, 426, 428, 429, 431

von Hippel-Lindau disease, 490  
V-raf murine sarcoma, 128

**W**

WAGR syndrome, 457  
Well-differentiated liposarcoma/atypical  
lipomatous tumor (WDLPS/ALT), 401,  
403, 410  
Western blot, 8  
WHO. *See* World Health Organization (WHO)  
Whole genome analysis, 271  
Wild type, 98, 107  
Wilms' tumor, 455, 457–459  
World Health Organization (WHO), 523, 524,  
526, 527, 535, 536, 543

**Y**

Yolk sac tumors (YST), 354

**Z**

Zinc-fingers, 455, 458  
WIT-1, 458  
WT-1, 458